Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901

S Han,Tingtsung Chang,Y C Chao,Seung Kew Yoon,Robert G Gish,Hugo Cheinquer,Flair Jose Carrilho, Hua Zhang,Helena Brettsmith,N Spiegelmacher,A Schwendel,T Pichl, I Reeb,R Hindes

Zeitschrift Fur Gastroenterologie（2008）

引用 4|浏览4

暂无评分

摘要

Aims: Entecavir (ETV) 0.5mg demonstrated superior virologic suppression compared to lamivudine (LVD) 100mg in study ETV-022. One hundred and eighty-three entecavir-treated patients from ETV-022 enrolled in rollover study ETV-901. We present efficacy and safety results in a cohort of patients from ETV studies -022 and -901 who received a total of 4 years of therapy with ETV.

查看译文

关键词

four-year

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要